Stroke medication to reduce risks
New stroke medication research has recently been commissioned by AstraZeneca. They have announced plans to conduct two new clinical studies as part of “PARTHENON”, AstraZeneca’s largest clinical trial program involving over 80,000 patients.
- The studies are designed to build scientific understanding of “ticagrelor tablets” in high-risk patients
A “TIA” (transient ischaemic attack) is a temporary insufficient blood supply to parts of the brain and requires swift intervention to reduce further risks.
The disruption in blood supply results in a lack of oxygen to the brain. The effects can last for a few minutes and are may be fully resolved within 24 hours. However, it is important to act “F.A.S.T.”
F.A.S.T. stands for “Face-Arms-Speech-Time”.
Face – the face may have fallen on one side, the person may be unable to smile, or their mouth or eye may have dropped
Arms – the person may not be able to raise both their arms and keep them there due to weakness or numbness in their arms
Speech – the person may have slurred speech
Time – if any of these signs or symptoms are present, it is time to dial 999 immediately
“SOCRATES” is a randomized study evaluating “ticagrelor” compared to aspirin in reducing major vascular events including risks relating to “TIA”. Clay Johnston, MD, commented: “The short-term stroke risk after a TIA and minor ischemic stroke is extremely high. More than 10 percent of patients have a major stroke within 90 days; and this is with aspirin. We need additional medicines in this setting and SOCRATES will tell us whether ticagrelor might be such a medicine,”
Bluecrest Health Screening welcomes all new research to better understand risks relating to TIA, Stroke and treatment options. The development of new stroke medication and treatments for those who have suffered TIA or stroke links closely with the NHS goals of FAST action to improve health outcomes.